Advertisement

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.

C M Coughlin, K E Salhany, M Wysocka, E Aruga, H Kurzawa, A E Chang, C A Hunter, J C Fox, G Trinchieri, and W M Lee

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Coughlin, C. in: JCI | PubMed | Google Scholar

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Salhany, K. in: JCI | PubMed | Google Scholar

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Wysocka, M. in: JCI | PubMed | Google Scholar

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Aruga, E. in: JCI | PubMed | Google Scholar

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Kurzawa, H. in: JCI | PubMed | Google Scholar

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Chang, A. in: JCI | PubMed | Google Scholar

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Hunter, C. in: JCI | PubMed | Google Scholar

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Fox, J. in: JCI | PubMed | Google Scholar

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Trinchieri, G. in: JCI | PubMed | Google Scholar

Biomedical Graduate Program, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Find articles by Lee, W. in: JCI | PubMed | Google Scholar

First published March 15, 1998 - More info

Published in Volume 101, Issue 6 on March 15, 1998
J Clin Invest. 1998;101(6):1441–1452. https://doi.org/10.1172/JCI1555.
Copyright © 1998, The American Society for Clinical Investigation.

First published March 15, 1998 - Version history
Abstract

The antitumor effect and mechanisms activated by murine IL-12 and IL-18, cytokines that induce IFN-gamma production, were studied using engineered SCK murine mammary carcinoma cells. In syngeneic A/J mice, SCK cells expressing mIL-12 or mIL-18 were less tumorigenic and formed tumors more slowly than control cells. Neither SCK.12 nor SCK.18 cells protected significantly against tumorigenesis by distant SCK cells. However, inoculation of the two cell types together synergistically protected 70% of mice from concurrently injected distant SCK cells and 30% of mice from SCK cells established 3 d earlier. Antibody neutralization studies revealed that the antitumor effects of secreted mIL-12 and mIL-18 required IFN-gamma. Interestingly, half the survivors of SCK.12 and/or SCK.18 cells developed protective immunity suggesting that anti-SCK immunity is unlikely to be responsible for protection. Instead, angiogenesis inhibition, assayed by Matrigel implants, appeared to be a property of both SCK.12 and SCK.18 cells and the two cell types together produced significantly greater systemic inhibition of angiogenesis. This suggests that inhibition of tumor angiogenesis is an important part of the systemic antitumor effect produced by mIL-12 and mIL-18.

Version history
  • Version 1 (March 15, 1998): No description
Advertisement
Advertisement